| P50 | author | Iñaki F. Trocóniz | Q38801515 |
| | Mats O Karlsson | Q88464853 |
| P2093 | author name string | Peter Nygren | |
| | France Mentré | |
| | Leon Aarons | |
| | Jean-Louis Steimer | |
| | Hans Schaefer | |
| | COST B15 Experts | |
| | Amy Racine | |
| | Anthony Man | |
| | Achiel van Peer | |
| | Ferdinand Rombout | |
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| | Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue | Q27863454 |
| | Clinical trial designs for cytostatic agents: are new approaches needed? | Q28141331 |
| | Genetic alterations during colorectal-tumor development | Q28281200 |
| | Joint modelling of longitudinal measurements and event time data. | Q30819896 |
| | Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors | Q31922419 |
| | Carboplatin dosage: prospective evaluation of a simple formula based on renal function | Q33429552 |
| | What is the optimal rodent model for anti-tumor drug testing? | Q33649337 |
| | Critical determinants of cancer metastasis: rationale for therapy | Q33651963 |
| | Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development | Q33767883 |
| | Content and quality of currently published phase II cancer trials | Q33818394 |
| | Role of the development scientist in compound lead selection and optimization | Q33846122 |
| | Matrix metalloproteinases: biologic activity and clinical implications | Q33849967 |
| | Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus | Q33882066 |
| | Simulation of clinical trials | Q33932132 |
| | Redefining the target: chemotherapeutics as antiangiogenics | Q34142103 |
| | Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer | Q34168931 |
| | Role of modelling and simulation in Phase I drug development | Q34215804 |
| | Prognostic and predictive factors in breast cancer | Q34288723 |
| | The Swedish Council on Technology Assessment in Health Care (SBU) report on Cancer Chemotherapy--Project objectives, the working process, key definitions and general aspects on cancer trial methodology and interpretation | Q34301158 |
| | What is cancer chemotherapy? | Q34301165 |
| | Assessment of quality of life during chemotherapy | Q34301172 |
| | Bcr-Abl inhibition as a modality of CML therapeutics | Q34366423 |
| | STI571: a paradigm of new agents for cancer therapeutics | Q34482385 |
| | Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer | Q34483005 |
| | Mode of action of docetaxel - a basis for combination with novel anticancer agents | Q35218002 |
| | Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients | Q35825206 |
| | Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents | Q36515822 |
| | Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses | Q40197212 |
| | High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity | Q40653373 |
| | Introduction to backpropagation neural network computation | Q40887964 |
| | Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative | Q41123160 |
| | On the relationship between response to treatment and survival time | Q41290338 |
| | Animal models and the molecular pathology of cancer | Q41447163 |
| | Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling | Q41628245 |
| | Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials | Q41685341 |
| | Regulatory considerations for preclinical development of anticancer drugs | Q41690433 |
| | The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. | Q41736480 |
| | Beware of contaminating mouse cells in human xenografts from nude mice. | Q41752712 |
| | Association of busulfan area under the curve with veno-occlusive disease following BMT. | Q42556319 |
| | Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study | Q43405330 |
| | Antineoplastic drug screening belongs in the laboratory, not in the clinic | Q43466173 |
| | Sensitivity analysis for nonrandom dropout: a local influence approach | Q43544467 |
| | Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. | Q43662609 |
| | Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. | Q43706400 |
| | A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. | Q43756965 |
| | Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes | Q43759371 |
| | Population pharmacokinetic analysis of the major metabolites of capecitabine | Q44113461 |
| | Model of chemotherapy-induced myelosuppression with parameter consistency across drugs | Q44253518 |
| | Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours | Q44370108 |
| | Designs for phase II trials allowing for a trade-off between response and toxicity | Q45101960 |
| | Continual reassessment designs with early termination | Q46316138 |
| | Optimal two-stage designs for phase II clinical trials | Q46412217 |
| | Interim analysis and sample size reassessment | Q47222981 |
| | Sample size determination for phase II clinical trials based on Bayesian decision theory | Q47291830 |
| | The validation of surrogate endpoints in meta-analyses of randomized experiments | Q47671365 |
| | There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture | Q48381754 |
| | Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. | Q48602300 |
| | Continual reassessment method: a practical design for phase 1 clinical trials in cancer | Q48901121 |
| | A curve-free method for phase I clinical trials. | Q52076810 |
| | Computational model of intracellular pharmacokinetics of paclitaxel. | Q52077082 |
| | A design alternative for two-stage, phase II, multicenter cancer clinical trials. | Q52235990 |
| | A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. | Q52245488 |
| | Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. | Q52250579 |
| | Improved designs for dose escalation studies using pharmacokinetic measurements. | Q52299033 |
| | Continual reassessment method: a likelihood approach. | Q52304573 |
| | Some practical improvements in the continual reassessment method for phase I studies | Q52338530 |
| | The continual reassessment method in cancer phase I clinical trials: a simulation study. | Q52394804 |
| | What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project. | Q52885097 |
| | Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis | Q59901778 |
| | Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients | Q71059806 |
| | A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer | Q71198607 |
| | Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer ( | Q72326598 |
| | A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer | Q73038578 |
| | Streptococcus pneumoniae pneumonia in mice: optimal amoxicillin dosing predicted from a pharmacokinetic-pharmacodynamic model | Q73192606 |
| | Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization | Q73443760 |
| | Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers | Q73456912 |
| | Accelerated titration designs for phase I clinical trials in oncology | Q73598986 |
| | Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group | Q73856268 |
| | Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches | Q74497643 |
| | Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? | Q74784070 |
| | Delivery of molecular and cellular medicine to solid tumors | Q77314470 |
| | In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents | Q77583377 |
| | Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388 | Q78198994 |
| | The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent | Q78846264 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 419-440 | |
| P577 | publication date | 2004-12-01 | |
| P1433 | published in | Journal of Pharmacokinetics and Pharmacodynamics | Q15766045 |
| P1476 | title | Modelling and simulation in the development and use of anti-cancer agents: an underused tool? | |
| P478 | volume | 31 | |